Clinical Predictors of Outcome in Advanced Adrenocortical Carcinoma: a multicentre international ENSAT study - PubMed
4 days ago
- #systemic therapy
- #adrenocortical carcinoma
- #prognostic tool
- Study evaluates clinical predictors of outcome in advanced adrenocortical carcinoma (ACC).
- Multicenter, international cohort study involving 418 patients from 11 centers.
- Patients received mitotane monotherapy, etoposide + doxorubicin + cisplatin ± mitotane, or second-line regimens.
- Key variables included age, cortisol excess, performance status (ECOG-PS), tumor burden, and neutrophil-to-lymphocyte ratio (NLR).
- Tumor burden, cortisol excess, ECOG-PS, and NLR ≥5 independently predicted shorter overall survival (OS).
- Developed ENSAT Risk Score for Advanced ACC combining tumor burden, cortisol excess, ECOG-PS, and NLR.
- Score >2 (poor-risk) associated with worse OS and time to progression (TTP) across all treatment groups.
- ENSAT Risk Score is a practical prognostic tool for advanced ACC patients receiving systemic therapy.
- Based on accessible clinical and biochemical markers, supports treatment decisions and informed discussions.